The Advanced Practice Provider Perspective: Treating Patients With Immuno-Oncology Combination Therapy Across Tumor Types

A number of immune checkpoint inhibitors (ICIs) have been approved by the U.S. Food and Drug Administration (FDA) as immuno-oncology (IO) monotherapy for multiple solid and hematologic tumor types across various lines of therapy. Furthermore, evidence shows some patients may derive additional benefi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffner, Brianna, Vaughn, Renae, Reed, Maureen, Weber, Melinda S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520742/
https://www.ncbi.nlm.nih.gov/pubmed/33343985
http://dx.doi.org/10.6004/jadpro.2019.10.4.5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520742/
https://www.ncbi.nlm.nih.gov/pubmed/33343985
http://dx.doi.org/10.6004/jadpro.2019.10.4.5

Ejemplares similares